Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity [letter] NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity [letter]

Biomed Pharmacother. 1999 Jun;53(5-6):286-7. Unique Identifier : AIDSLINE MED/99353097
Quirino T; Bonfanti P; Arcidiacono M; Pusterla L; Cagni A; Scaglione F; Milazzo F

Abstract: This trial was conducted to study the frequency of the slow acetylator phenotype in asymptomatic HIV patients having no previous reaction to sulfa-drugs, and to compare this frequency with the frequency found in healthy controls. Results show that HIV alone is not capable of modifying the acetylator phenotype; the prevalence of slow acetylator phenotype is the same in immune competent subjects and HIV-positive patients. It is more common in HIV-positive patients with a CD4+ lymphocyte count of less than 200 mm-3.
Keywords: CLINICAL TRIAL LETTER JOURNAL ARTICLE Acetylation Adult Anti-Infective Agents/*ADVERSE EFFECTS Drug Hypersensitivity/EPIDEMIOLOGY/*GENETICS Female Human HIV Infections/*GENETICS/METABOLISM HIV Seropositivity Kinetics Male Phenotype Support, Non-U.S. Gov't Trimethoprim-Sulfamethoxazole Combination/*ADVERSE EFFECTSKWDclinicaltrialletterjournalarticleacetylationadultanti-infectiveagents/KWDadverseeffectsdrughypersensitivity/epidemiology/KWDgeneticsfemalehumanhivinfections/KWDgenetics/metabolismhivseropositivitykineticsmalephenotypesupport,non-uKWDsKWDgov'ttrimethoprim-sulfamethoxazolecombination/KWDadverseeffects
991230
A99C1033

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .